Eloxx Pharmaceuticals, Inc.

( )
ELOX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
GILDGilead Sciences, Inc. 0.01%75.001.0%$1746.54m
AMGNAmgen, Inc. -0.64%217.791.3%$925.22m
REGNRegeneron Pharmaceuticals, Inc. -0.92%507.642.6%$838.50m
BIIBBiogen, Inc. -0.64%314.921.5%$800.53m
VRTXVertex Pharmaceuticals, Inc. -0.46%248.521.9%$654.48m
MRNAModerna, Inc. 0.25%32.500.0%$511.91m
ILMNIllumina, Inc. -0.48%279.643.5%$489.45m
ALXNAlexion Pharmaceuticals, Inc. 4.05%98.562.0%$309.13m
AAgilent Technologies, Inc. 3.58%76.681.6%$228.40m
INCYIncyte Corp. -0.34%87.452.5%$220.29m
EXASEXACT Sciences Corp. 6.02%66.3721.0%$182.14m
SGENSeattle Genetics, Inc. -0.64%118.916.1%$160.26m
BMRNBioMarin Pharmaceutical, Inc. -0.64%79.094.3%$149.60m
NVAXNovavax, Inc. 2.45%17.60114.7%$138.97m
IMMUImmunomedics, Inc. -2.54%18.4311.9%$121.13m

Company Profile

Eloxx Pharmaceuticals, Inc. engages in the development of novel ribonucleic acid modulating drug candidates. The firm focuses on the the formulation of medicines to treat rare and ultra-rare premature stop codon diseases. It operates through the United States and Israel geographical segments. Its product includes ELX-02, a small molecule drug designed to restore production of full-length functional proteins which treats cystic fibrosis and cystinosis. The company was founded by Silvia Noiman on December 19, 2017 and is headquartered in Waltham, MA.